Key Stats for JNJ Stock
- Past week’s performance: -1.3%
- 52-week range: $146 to $252
- Valuation model target price: $279
- Implied upside: +25.9% over 2.6 years
Value your favorite stocks like JNJ with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Johnson & Johnson (JNJ) is one of the world’s largest pharmaceutical and medical technology companies. Its Innovative Medicine segment develops treatments for cancer, immunology, and infectious diseases. Its MedTech segment covers surgical robotics, orthopedic devices, and vision care. JNJ stock dipped just 1.3% this week, so the more meaningful story is the broader momentum that has driven shares up roughly 43% over the past year.
The most significant recent catalyst was the FDA approval of Icotyde, also known as Icotrokinra, in March 2026 for first-line plaque psoriasis treatment. That approval introduced a first-in-class oral peptide into JNJ’s immunology portfolio, creating a competitive edge in a large and growing dermatology market. Separately, the European Commission approved AKEEGA for BRCA1/2-mutated prostate cancer, further expanding the oncology franchise.
On the MedTech side, JNJ’s Ottava surgical robot met safety and performance endpoints in a gastric bypass study, representing a meaningful step toward commercial launch. Management is also exploring a $20 billion-plus sale of DePuy Synthes, its orthopedics unit, which could sharpen the company’s strategic focus on higher-growth pharma and robotics.
However, CVS recently dropped Stelara, a key immunology drug, from its main formularies, adding a near-term revenue headwind. If JNJ stock is to sustain its rally, investors will need pipeline execution to outpace drug pricing headwinds and formulary pressures in the months ahead.
See analysts’ growth forecasts and price targets for JNJ (It’s free) >>>
Is JNJ Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 6.8%
- Operating Margins: 34.8%
- Exit P/E Multiple: 18x
Based on these inputs, the model estimates a target price of $279, implying a 25.9% total return from the current share price and an annualized return of 9.1% over the next 2.6 years.
At 9.1% annualized, the model signals modest but real upside from today’s price. For a company of JNJ’s size and maturity, this level of return is reasonable but not compelling for growth-oriented investors. Stocks returning under 10% annually sit in a gray zone, acceptable for income-focused portfolios but unlikely to attract momentum buyers at current levels.
Revenue CAGR of 6.8% reflects JNJ’s post-Kenvue identity as a focused pharmaceutical and MedTech business. The company divested its consumer health segment in 2023, and what remains carries significantly higher margins. A gross margin of 68% and an LTM operating margin of 27.6% both confirm the quality of the remaining business, and the model assumes those margins expand further to 34.8% by 2028.
Near-term pricing pressure is a real risk. JNJ’s CFO stated that 2026 guidance already factors in hundreds of millions of dollars of impact from a most-favored-nation drug pricing agreement with the Trump administration. Also, the CVS formulary drop for Stelara adds revenue uncertainty. So the modest model return already reflects a cautious view of the macro drug-pricing environment.
What’s Driving JNJ Stock Going Forward?
The pharmaceutical pipeline is JNJ’s most important long-term growth engine. The Icotyde approval in March 2026 marks a new generation of oral peptide therapies in dermatology. Management also presented late-breaking Phase 3 data for Erleada in prostate cancer at ASCO in April 2026, which could expand that drug’s use into earlier disease stages and a larger patient population.
MedTech is the second key engine. JNJ’s Ottava surgical robot is progressing through clinical validation, and a commercial launch would place it in direct competition with Intuitive Surgical’s da Vinci platform. Surgical robotics is a multibillion-dollar market, and JNJ enters it with an established hospital sales force and deep existing relationships.
A potential DePuy Synthes sale is a major strategic event to watch closely. Bloomberg reported in February 2026 that JNJ is exploring a divestiture worth more than $20 billion. If completed, the sale would unlock capital and allow JNJ to focus entirely on its highest-growth businesses in oncology, immunology, and robotics.
JNJ targets approximately $21 billion in free cash flow for 2026, and the company paid a $1.34 per-share quarterly dividend in May. The dividend yield of 2.4% and a payout ratio of 59.5% mean the distribution is comfortably covered. JNJ also presents at the Bank of America Global Healthcare Conference on May 12, which may provide updated commentary on the pipeline.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JNJ, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track JNJ alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze JNJ stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
